About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Find trials: by AGENT | by TYPE of LYMPHOMA AND treatment status | of INTEREST

   Search Site | Ask Question | Sign Guest book |  How to Help!

Patients Against Lymphoma

 

Types of Lymphoma > T-Cell Lymphoma

Last updated: 03/13/2014

TOPICS
Types of T-cell Lymphomas

Introduction | Types | Cooperative Research Centers | Clinical TrialsOutcome Abstracts   

TOPIC SEARCH: PubMed: Diagnosis | Review | Therapies | Prognosis  

In the News:

bullet
ASCO Post:
“Molecular Profiling Improves Classification of Nodal Peripheral T-Cell Lymphomas
By Matthew Stenger” http://bit.ly/1ihlRMO

ASCO Post: Viewpoint:
Molecular Profiling Improves Classification of
Nodal Peripheral T-Cell Lymphomas - Horwitz, MD http://bit.ly/1fzstWp
bullet
Mogo report at ASH 2013 looks promising (PAL)
bullet
Dr. Andrei Shustov video presentation: T-cell lymphomas -
New therapies and clinical trials http://bit.ly/16HuxYp
bullet
Oncology Times: PTCL: Should Initial Management Include
High-Dose Therapy with Autologous Stem Cell Rescue?
http://bit.ly/15nsV5x 

See also

the Lymphatic System

and Lymphoma Simplified

"Lymphoma is a blood cell cancer.  The effected cells are called lymphocytes, a type of white blood cell that helps protect us from infection." 

See also Lymphoma Overview

About 85% of lymphomas are of b-cell origin, and 15% of t-cell origin.  

B-cells originate and mature (differentiate) in the bone marrow. 

T-cells
also start out in the bone marrow, but they differentiate and mature in the thymus gland. 

Natural Killer cells are a third kind of lymphocyte. They specialize in killing foreign cells and possibly signaling to alert other immune cells of invaders.

The different types of lymphoma are determined according to what type of lymphocyte has become cancerous and the maturation stage of the abnormal cell. As with other cancers, the cause of lymphoma is damage to genes that leads to abnormal growth controls in the cell. 

* CCR, 2010: New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies http://clincancerres.aacrjournals.org/content/16/23/5608.full

Image comparing outcomes based on subtype.

Types of T-cell Lymphomas

Most Common

bullet
Mycosis fungoides (MF) (indolent)
bullet
Transformed MF (aggressive)
bullet
Sézary's syndrome (indolent)
bullet

Peripheral T-cell Lymphoma, unspecified (aggressive)
The most common t-cell lymphoma - 57%

 

NK and Blastic (aggressive)

bullet
Blastic NK-Cell  lymphoma

Lymphoblastic  Lymphoma
 

NK = natural killer cell 
Blastic = presenting in blood

Precursor

(immature cell -  aggressive)

bullet
Precursor T/NK cell leukemia/lymphoma

Cutaneous Presenting in skin

bullet
Mycosis fungoides (MF) (indolent)
bullet
Transformed MF (aggressive)
bullet
Sézary's syndrome (indolent)
bullet
Subcutaneous panniculitis-like T-cell lymphoma
onlinelibrary.wiley.com
 
bullet
Primary cutaneous (skin) CD30+ disorders: 
bullet
Anaplastic large-cell lymphoma
(ALCL) aggressive
bullet
Lymphomatoid papulosis

Extranodal 

Presenting outside lymph system

bullet
Enteropathy type
Intestinal (aggressive)
bullet
Hepatosplenic T-cell Lymphoma  PubMed
Liver/spleen: (aggressive)
bullet
Peripheral T/NK-cell lymphoma
Unspecified (aggressive) 
 (see also Nodal) 
bullet
Nasal: T/NK cell lymphoma  (aggressive)
bullet
Subcutaneous:  panniculitis T-cell Lymphoma (aggressive)

Subcutaneous = under skin
Panniculitis = layer of subcutaneous fat under epidermis of the skin.


About  Doctorsdoctor.com

Return to top

Nodal 
Presenting in lymph nodes

bullet
Anaplastic large-cell lymphoma,
primary systemic type (aggressive)
bullet
Angioimmunoblastic T-cell lymphoma
(aggressive)
bullet
Peripheral T-cell Lymphoma, unspecified (aggressive) (57%)

Leukemic 
Presenting in blood

bullet
Adult T-cell lymphoma/leukemia
(HTLV1+) (aggressive)

HTLV = human t-cell leukemia virus
bullet
T/NK cell leukemia/lymphoma (aggressive)
bullet
T-cell large granular lymphocytic leukemia 
bullet
T-cell prolymphocytic leukemia (T-PLL)

Blood, 2012: How I treat prolymphocytic leukemia by Claire Dearden bloodjournal.hematology

This is a rare type of lymphoma with an aggressive clinical course - however it sometimes behaves indolently and can be observed instead of treated initially sometimes for as long as 2 years. The author notes that "progression may occur rapidly, and I therefore monitor these patients more closely than I would a patient with stage A CLL. This will often allow time to identify a suitable donor if allogeneic transplant is planned so that there will be no delays once treatment with alemtuzumab is initiated."

Topic Search: PubMed
Trial Search: ClinicalTrials.gov

Other

bullet
CLL/prolymphocytic lymphoma
bullet
Also see NK cell Lymphoma
bullet
Gamma-delta T-cell phenotype
(provisional subtype)
bullet
Lymphomatoid T-cell lymphoma
(uncertain malignant status)

 

 

 

Abbreviations

 ALCL = anaplastic large cell lymphoma 
AITL Angioimmunoblastic T-cell lymphoma
Blastic = presenting in blood 
Cutaneous = presenting in skin 

Extranodal = other than lymph nodes
 HTLV = human t-cell leukemia virus
 Leukemic = malignant leukocyte, presenting in blood
Lymphoma = malignant lymphocyte, belonging to lymphatic system 

T-PLL = T-cell prolymphocytic leukemia | 
MF = mycosis fungoides
Neoplasms = abnormal cell growth and survival (malignant)
Nodal = involving lymph nodes
NK = natural killer cell

Precursor =  cell in early phase of maturity
PTCL = peripheral t-cell lymphoma NOS = Not otherwise specified

Return to top

 

Introduction

T-cell lymphomas are a family of blood cell cancers

Lymphoma is a blood cell cancer - a condition where abnormal lymphocytes (a type of white blood cell) expand in number forming tumors often in lymph nodes but also in other regions, such as the bone marrow.   See also the Lymphatic System and Lymphoma Simplified 

Incidence: "Non-Hodgkin's Lymphomas caused by malignant (cancerous) T-Cell lymphocytes represent a smaller subset (about 15% in the US) of the known types of non--Hodgkin's lymphoma - approximately 6,885 new cases diagnosed annually.

There are many types of t-cell lymphomas, based on the cell of origin and areas of presentation.  An accurate diagnosis will allow you to choose the most appropriate therapy.  For example,  for a lymphoma type with an aggressive clinical course, therapy with curative intent can be most appropriate. Otherwise, a management approach might be chosen - treating as needed with less toxic protocols.  
 

Background Articles and News

bullet
Latif and Morris:

Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma:  http://bit.ly/WimCgm
bullet
ASH 2012 - T-cell lymphoma abstracts compiled by PAL
bullet
ASCO 2012 - T-cell lymphoma abstracts compiled by PAL
bullet
ISRN Hematol. 2011; A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
bullet
T-cell - Cancer: Increasing incidence of Enteropathy-associated T-cell lymphoma in  US, 1973-2008.
bullet
T-Cell - Weill Cornell, Dr. Ruan: ASH 2011: New Treatment for T-Cell Lymphoma
bullet
2010 - Biol Blood Marrow Transplant: Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience  

"The pre-transplant factors that impacted survival were disease status and the number of prior regimens. Histology, age, sex, stage, B symptoms, bone marrow involvement, and duration of first response did not significantly affect PFS or OS.

Based on these results, AHCT as consolidation therapy in first complete or partial response may offer a durable survival benefit.

However, AHCT with conventional salvage chemotherapy has minimal durable benefit in patients with relapsed or refractory PTCL, and thus novel strategies and/or allogeneic HCT should be more aggressively explored in lieu of AHCT for relapsed/ refractory PTCL."
bullet
Technical: Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms
bullet
Surviving Adult T-cell Leukemia/Lymphoma 
bullet
ASH 2010 Abstracts  

Centers

Engaged in Cooperative Research in T-cell Lymphomas

North America

Europe

Asia

 

Return to top

North American Centers
 
Engaged in Cooperative Research: T-cell Lymphomas

Australia,  Radiation Oncology, Peter MacCallum Cancer Centre, East Melbourne

Canada British Columbia Cancer Agency, Vancouver, BC

Canada Medical Oncology and Hematology, Princess Margaret Hospital, Toronto

Canada Medical Oncology, British Columbia Cancer Agency, Vancouver, BC

Canada Pathology, British Columbia Cancer Agency, Vancouver, BC

CA City of Hope National Medical Center, Duarte

CA Stanford School of Medicine, Stanford

CA UCLA, Los Angeles

CT Yale Medical Oncology, New Haven

FL H. Lee Moffitt Cancer Center and Research Institute, Tampa

GA Emory University Hospital, Atlanta

GA Winship Cancer Institute, School of Medicine, Emory University, Atlanta

IA University of Iowa, Iowa City

MA Dana-Farber Cancer Institute, Boston

MO Washington University School of Medicine, St. Louis

NE Hematology/Oncology, University of Nebraska Medical Center, Omaha

NE Pathology, University of Nebraska Medical Center, Omaha

NJ The John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

NY Department of Medicine, NYU Cancer Institute, NYU Langone Medical Canter, New York

NY Hematology/Oncology, New York Univ. Clinical Care Center, New York

NY Hematology/Oncology, NYU Langone Medical Center, New York

NY Memorial Sloan-Kettering Cancer Center, New York

NY New York University Cancer Institute, New York

NY Univ. of Rochester Med. Ctr., Rochester

PA Fox Chase Cancer Center, Philadelphia

TX Dermatology, UT MD Anderson Cancer Center, Houston

TX Institute for Drug Development, CTRC at UT Health Science Center at San Antonio

TX University of Texas MD Anderson Cancer Center, Houston

WA University of Washington, Seattle

 

European Centers
Engaged in Cooperative Research in T-cell Lymphomas

Department of Cancer Epidemiology, Lund University, Lund, Sweden
Department of Haematology, Midwestern Regional Hospital, Limerick. Ireland, Limerick, Ireland
Department of Hematology, Aarhus University Hospital, Aarhus C, Denmark
Department of Hematology, Karolinska Institutet, Stockholm, Sweden
Department of Internal Medicine, Vejle Hospital, Vejle, Denmark
Department of Medicine, Kuopio University Hospital, Kuopio, Finland
Department of Oncology, Karolinska University Hospital, Karolinska, Sweden
Department of Oncology, Lund University Hospital, Lund, Sweden
Department of Oncology, Oslo University Hospital, Oslo, Norway
Department of Oncology, Oulu University Hospital, Oulu, Finland
Department of Oncology, St. Olav University Hospital Tronheim, Tronheim, Norway
Department of Oncology, Ullevål Oslo University Hospital, Ullevål, Norway
Department of Oncology, Umeå University Hospital, Umeå, Sweden
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark
Department of Pathology, Oslo University Hospital, Oslo, Norway
Department of Pathology, Tampere University Hospital, Tampere, Finland
Dept. of Hematology, Copenhagen University Hospital, Copenhagen, Denmark
Dept. of Pathology, Uppsala University Hospital, Uppsala, Sweden
Hospices Civils de Lyon, Lyon, France
Hospital Universitario, Salamanca, Spain
Institue of Cancer Resch/Royal Marsden, Sutton, Surrey, England
Institue of Cancer Resch/Royal Marsden, Sutton, Surrey, England
Klinikum Nuernberg, Nuernberg, Germany
Royal North Shore Hospital, St Leonards, Australia
TopoTarget, Copenhagen, Denmark
University Hospital Cologne, Cologne, Germany
University Hospital of Lille, Lille, France
University Hospital Rigshospitalet, Copenhagen, Denmark

 

Asians Centers
Engaged in Cooperative Research in T-cell Lymphomas

Clinical Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Department of Hematology and Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University Hospital, Nagasaki, Japan
Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Dept. of Hematology, Imamura Bun-in Hospital, Kagoshima, Japan
Development Division, Kyowa Hakko Kirin Co., Ltd., Chiyoda-ku, Japan
Graduate School of Med. Bioregulatory Medicine, Ehime University, Toon, Japan
Hematology & Cell Therapy, Aichi Cancer Center, Nagoya, Japan
Hematology and Immunology, NTT West Kyushu Hsp, Kumamoto, Japan
Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
Hematology, Kumamoto Medical Ctr, Kumamoto, Japan
Hematology, Nagasaki Medical Ctr, Omura, Japan
Hematology, Oita Prefectural Hsp, Oita, Japan
Int Med, Japanese Red Cross Nagasaki Genbaku Hsp, Nagasaki, Japan
Internal Medicine, Division of Hematology and Oncology, Fukuoka University, Fukuoka, Japan
Medicine and Biosystemic Science, Kyushu University Hospital, Fukuoka, Japan
School of Medicine Dept. of Hem., Kumamoto Univ., Kumamoto, Japan

 

Return to top
 

CLASSIFYING  lymphomas:
The categories appear to correspond to biological entities that behave distinctly. 
Gives the clinician important guidance for treating the lymphoma
Helps assess prognosis.
Helps  pathologist to recognize a lymphoma.
Helps discover important biological principles that underlie their appearance and behavior.
SOURCE: - 
UMDNJ Hematopathology
Return to top

 

CLINICAL TRIALS

All T-cell Types:
bullet
Newly diagnosed or untreated 
bullet
Recurrent
By Subtype:
Anaplastic Large Cell type: 
Newly diagnosed or  previously untreated
  AND Recurrent
bullet
Angioimmunoblastic untreated  | relapsed | with stem cell transplant
bullet
Cutaneous T-cell lymphoma untreated  | relapsed
bullet
NK Cell 
bullet
PTCL (Peripheral T-cell Lymphoma) 
 

RESOURCES

bullet
Non-Hodgkins Lymphomas Clinical Practice Guidelines in Oncology – v.1.2006  NCCN.org  PDF  
bullet
Antibodies for T-Cell NHL
bullet
T-cell lymphomas UMDNJ Hematopathology  
About normal t-cells and NK cells (cells of origin)
bullet
Normal T-cells  
 
GSU.edu
| Maturation - Virginia.edu |
and Cellular Immunity - Merck Manual 
bullet
Normal NK cells  Users.rcn.com/jkimball.ma.ultranet

Return to top

Adult T-cell Lymphoma/leukemia

 
Return to top
bullet
About  demon.co.uk 
bullet
Encouraging report: Arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed adult T-cell leukemia/lymphoma (ATL). http://bit.ly/3t5gvg 

n = 10 newly diagnosed ATL

An impressive 100 percent response rate was observed including 7 complete remissions, 2 complete remissions but with more than 5% circulating atypical lymphocytes, and 1 partial response. Responses were rapid and no relapse was noted. Side effects were moderate and mostly hematologic. In conclusion, treatment of chronic ATL with arsenic, interferon-alpha, and zidovudine is feasible and exhibits an impressive response rate with moderate toxicity.

bullet
Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002 Sep 1;100(5):1828-34. PMID: 12176906  PubMed

Return to top

 

Anaplastic Large Cell Lymphoma

 
Return to top

We have moved this item here

Also see Childhood NHL - Anaplastic Large Cell


T-cell large granular lymphocytic leukemia (LGL)

 
Return to top


"LGL exhibits an unexplained, chronic elevation in large granular lymphocytes (LGLs) in the peripheral blood.

It is also known by the following terms: Proliferation of large granular lymphocytes (LGLs), LGL leukemia, Tγ-lymphoproliferative disorder, T-cell chronic lymphocytic leukemia"  1 

LGL has an indolent clinical course mortality is uncommon (rarely fatal).2

"Some patients with mild cytopenias (low blood counts) and/or lymphocytosis remain asymptomatic for a long period. Spontaneous remissions have been reported in some studies. In symptomatic cases (majority) treatment should be initiated. Being a rare malignancy, treatment recommendations are based on data coming from case reports and retrospective studies. Recurrent neutropenia and infections are the main concern in treatment of this disease." 3

LGL is "a clonal proliferation of cytotoxic T cells, which causes neutropenia, anemia, and/or thrombocytopenia. This condition is often associated with autoimmune disorders, especially rheumatoid arthritis, and other lymphoproliferative disorders". 4

Resources:

  1. Wikipedia.org 
  2. atlasgeneticsoncology.org/ 
  3. doctorslounge.com 
  4. theoncologist 

    (most comprehensive description)

Return to top


Angiocentric Lymphoma (nasal T-cell Lymphoma)

 
Return to top

 

 

TOPIC SEARCH: 
ASCO
| Cancer.gov |
Clinical Trials | Medscape | PubMed

"Angiocentric lymphoma is a type of T-cell lymphoma that is associated with Epstein Barr virus (EBV) infection. It includes cancers that previously were labeled "lethal midline granulomas," "nasal T-cell lymphoma," and "lymphatoid granulomatosis." 

Angiocentric lymphoma typically is characterized by a destructive nasal or midline facial tumor that is accompanied by invasive infiltrate, a substance that penetrates the spaces between tissues. 

The patient's palate (roof of mouth) may be destroyed by the tumor, and he or she may have prominent swelling of the eyes and face. 

Other sites of involvement outside the lymph nodes (extranodal) are the skin, lungs, and central nervous system. This tumor often is very resistant to therapy and has a poor prognosis. It is much more common in Asians than in people of European descent." source:  oncologyChannel 
 

Resources & Research News

bullet
Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001; 61: 261-9. Abstract | Related articles   

Return to top


Angioimmunoblastic Lymphoma

 
Also see Peripheral T- cell lymphoma below

"While not always malignant, AILD commonly progresses to an AILD-like T cell lymphoma."

source: hsc.virginia.edu 

Return to top

 

PubMed TOPIC SEARCH 
Diagnosis
| Prognosis | Review | Treatment 

Angioimmunoblastic T-cell lymphoma (AILD) is considered a variety of T-cell lymphoma, which usually occurs in adults. 

Symptoms include generalized lymphadenopathy (enlarged lymph nodes) and increased antibody proteins in the blood (hypergammaglobinemia).  Other symptoms are fever, skin rash and weight loss. 

bullet
About emedicine.com  
bullet
High-Dose Therapy (HDT) and Autologous Stem-Cell Transplantation (ASCT) in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome  J Clin Oncol. 2007 Dec 10;   PMID: 18071187 

This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results.
bullet
Clinical, biological and pathological features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood. 2008 Feb 21; PMID: 18292286
bullet
Angioimmunoblastic lymphadenopathy with dysproteinemia: 
emphasis on pathogenesis and treatment. Acta Haematol. 1998;99(2):57-64. Review. PMID: 9554450   PubMed
bullet
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer. 1992 May 15;69(10):2567-70. PMID: 1568181   PubMed
bullet
Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports. Leuk Lymphoma. 2002 Jan;43(1):133-7. PMID: 11908717  PubMed
bullet
Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL? Leukemia. 2002 Oct;16(10):2134-41. PMID: 12357368  PubMed

ClinicalTrials.gov listings of clinical trials:

bullet
Angioimmunoblastic type | with stem cell transplant
bullet
TIPS:
bullet
Select Results on Map to find studies in your region for the above queries.
bullet
Because these are uncommon lymphomas, it's important to consult experts at centers that specialize in this research and work cooperatively to do trials.  

See Centers

Return to top


Lymphoblastic Lymphoma 
(predominantly t-cell) / Blastic Lymphoma

Lymphoblastic Lymphoma 

TOPIC SEARCH:  PubMed

Lymphoblastic lymphoma is a very rare form of non-Hodgkin lymphoma in adults, accounting for less than 3 in 100 cases overall. However, it accounts for more than 1 in 3 of all cases occurring in children and teenagers.  This lymphoma more commonly affects males than females. 

It's a high grade (aggressive) lymphoma which arise from precursors of B or T-cells.  In 4 out of 5 cases the T-lymphocytes are affected. The vast majority (90%) are of immature T-cell lineage. 

Clinical Trials for Lymphoblastic (b or t cell):
bullet
Previously Untreated
bullet
Relapsed
bullet
Relapsed, but ineligible for SCT
bullet
TIPS:
bullet
Select Results on Map to find studies in your region for the above queries.
bullet
Because these are uncommon lymphomas, it's important to consult experts at centers that specialize in this research and work cooperatively to do trials.  

See Centers

Presentation: 

bullet The thymus gland, or lymph nodes deep within the chest
(the mediastinal lymph nodes) is often affected. 

Signs: (common to other conditions)

bullet Painless swelling in the neck, armpit or groin, caused by enlarged lymph nodes.
 
bullet Loss of appetite and tiredness.

 
Resources

bullet
About Lymphoblastic lymphoma  E-medicine
bullet
Treatment best practice NCCN.org  PDF
(Login required. Now difficult to find on site)

Reports

bullet
Nine-Year Survival of Lymphoblastic Lymphoma Patients (full text report)
ncbi.nlm.nih.gov
bullet
Adult lymphoblastic lymphoma: a retrospective analysis of 92 patients under 61 years included in the LNH87/93 trials 
ncbi.nlm.nih.gov/
bullet
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
bloodjournal.hematologylibrary.org

"The results of the hyper-CVAD regimen in LL were very encouraging. Overall, 91% of patients achieved CR, and the estimated 3-year overall survival rate was 70%, with a PFS rate of 66% "

Maintenance included 6-mercaptopurine (6-MP), methotrexate, vincristine, and prednisone (
POMP) for 24 months.
bullet
High-dose therapy and autologous stem-cell transplantation vs. conventional-dose consolidation/maintenance therapy as post-remission therapy for adult patients with lymphoblastic lymphoma ncbi.nlm.nih.gov
bullet
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and leukemia group B study 19801. Blood. 2007 Mar 7;
PMID: 17344466  
bullet
FDA Advisory Committee Recommends Accelerated Approval of GlaxoSmithKline's Arranon (nelarabine) Injection  docguide.com
Orphan Drug Under Review for Children and Adults with T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL)
bullet
Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
Ann Hematol. 2001;80 Suppl 3:B73-6.
PMID: 11757713

Blastic cell origin - T-cell lymphoma

"Blastic" generally refers to immature-looking cells that resemble cells known as a blasts.

  1. Genomic Alterations in Blastic Natural Killer/Extranodal Natural Killer-Like T Cell Lymphoma with Cutaneous Involvement - abstract ~ www.jidonline.org
bullet
TIP:
bullet
Because these are uncommon lymphomas, it's important to consult experts at centers that specialize in this research and work cooperatively to do trials.  

See Centers

Return to top

 

 
Cutaneous T-cell Lymphoma

Return to top

 

Cutaneous T cell lymphoma (CTCL) is a lymphoma of T cell (a type of white blood cell that is responsible for immune function) origin that affects the skin. 

See CTCL


Enteropathy type T-cell lymphoma

 Also see Peripheral T-cell lymphoma below
 

"This aggressive [intestinal] lymphoma almost always arises in the setting of celiac disease. Rarely the lymphoma may arise in extraintestinal sites. The most common location is the jejunum and presents as single or multiple tumors." Source: DoctorsDoctor

bullet
About  DoctorsDoctor | hmds.org.uk
bullet
A case study  phenopath.com 
bullet
Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol. 2006 Nov 20;  PMID: 17116129 
 
Enteropathy-associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease, with a poor prognosis due to perforation and gastro-intestinal bleeding during treatment, and a high relapse risk. Six patients were treated with two cycles of IVE (ifosphamide, etoposide, epirubicin), followed by two cycles of high-dose methotrexate (3 g/m(2)) with folinic acid rescue and a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Enteral feeding was given throughout treatment. Four patients remain alive in complete remission at 1.83-4.32 years; two have relapsed. Given the historically poor outcome in these patients, this regimen appears very promising in the treatment of EATL.
bullet
Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center.  http://jco.ascopubs.org

Clinical Trials

bullet
Phase II Trial of Depsipeptide in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma Number: 01-C-0049  NIH.gov
bullet
Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkinlymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?  BLOOD  (Scroll down to study in list.)
bullet
TIP:
bullet
Because these are uncommon lymphomas, it's important to consult experts at centers that specialize in this research and work cooperatively to do trials.  

See Centers

Return to top


Hepatosplenic

Return to top
bullet
About Hepatosplenic gamma-delta T-cell lymphoma  www.thedoctorsdoctor.com
bullet
Long-Term Survival With Allogeneic Stem Cell Transplant and Donor Lymphocyte Infusion Following Salvage Therapy with Anti-CD52 Monoclonal Antibody (Campath) in a Patient with alpha/beta Hepatosplenic T-Cell Non-Hodgkin's Lymphoma. Leuk Lymphoma. 2004;45(8):1673-1675. PMID: 15370223 
bullet
TIP:
bullet
Because these are uncommon lymphomas, it's important to consult experts at centers that specialize in this research and work cooperatively to do trials.  

See Centers


NK-Cell Lymphoma

Return to top

 Go NK Cell Lymphoma

 


Peripheral T- cell lymphoma, unspecified

Return to top

  Go to Peripheral T-cell

 


Subcutaneous panniculitis-like T-cell lymphoma

Return to top
"Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an uncommon cutaneous lymphoma that has been proposed as a distinct clinicopathologic entity, but studies of SPTCL are limited."  Source: nci.nih.gov
 
bullet
About  thedoctorsdoctor.com | archderm - PDF 
bullet
TIP:
bullet
Because these are uncommon lymphomas, it's important to consult experts at centers that specialize in this research and work cooperatively to do trials.  

See Centers

 

Resources & Research News

bullet
Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature.
Am J Dermatopathol. 2001 Jun;23(3):206-15. Review. PMID: 11391101  PubMed
bullet
Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol. 2000 Aug;143(2):408-10.
PMID: 10951154   PubMed 
bullet
Subcutaneous panniculitic T-cell lymphoma and cytophagic histiocytic panniculitis.
Australas J Dermatol. 2001 Aug;42(3):183-7. Review. PMID: 11488712  PubMed
bullet
Subcutaneous T-cell lymphoma presenting as panniculitis in children: report of two cases. Pediatr Pathol. 1994 Jul-Aug;14(4):595-608. PMID: 7971579  PubMed
bullet
Cutaneous T-cell lymphoproliferative disorders: approach for the surgical pathologist: recent advances and clarification of confused issues. Adv Anat Pathol. 2002 Mar;9(2):79-100. Review. PMID: 11917163  PubMed

Return to top

 
Estimating outcome & Survival

 

TOPIC SEARCH:- PubMed

Outcome abstracts:

bullet
Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003 Sep 1;98(5):993-1001. PMID: 12942567
bullet
A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma. Ann Hematol. 2002 May;81(5):267-72. PMID: 12029536  PubMed
bullet
T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma. 2002 Apr;43(4):805-11. PMID: 12153168  PubMed
bullet
The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas. Br J Haematol. 2002 Sep;118(4):1019-26. PMID: 12199780  PubMed

Return to top

 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.